patrick.net

NEW HAVEN, Conn., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Bexorg, Inc., the first integrated AI and whole-human brain platform company transforming central nervous system (CNS) drug discovery and development, today announced the completion of a $23 million Series A financing led by Engine Ventures with participation from new investors Connecticut Innovations and E1 Ventures and existing investors Amplify Partners and Starbloom Capital. Bexorg has raised a total of $42.5 million to date.

Industry reports have found that the clinical trial failure rate in CNS drug development exceeds 95%, largely because cellular and animal models used in drug discovery inaccurately capture human biology. Bexorg is shifting this paradigm, with its platform based on comprehensive human datasets generated from wet-lab experimentation in a living system of diseased and non-diseased whole human brains. This data directly feeds AI models to generate high-fidelity targets, novel biomarkers, and go/no-go decisions with unprecedented accuracy and reliability.

“The support from this group of leading investors validates that Bexorg has established a new category of AI-enabled, whole human-brain infrastructure for drug discovery that identifies novel targets and biomarkers, unlocking new biology and opportunities in CNS drug development,” said Zvonimir Vrselja, M.D., Ph.D., CEO and Co-founder of Bexorg. “Through our platform, using donated whole human brains, we restore specific molecular activities essential for drug discovery, while the higher-level brain functions are not restored — honoring each gift by generating a depth of knowledge that could not be gained otherwise.”

https://finance.yahoo.com/news/bexorg-raises-42-5m-transform-110000690.html